Cellectar Biosciences (NASDAQ:CLRB – Get Rating) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10), MarketWatch Earnings reports.
NASDAQ CLRB traded down $0.01 on Wednesday, hitting $0.39. 196 shares of the stock were exchanged, compared to its average volume of 198,383. Cellectar Biosciences has a 52-week low of $0.40 and a 52-week high of $1.84. The company has a market capitalization of $23.68 million, a price-to-earnings ratio of -0.88 and a beta of 1.58. The company’s 50-day moving average price is $0.58 and its two-hundred day moving average price is $0.65.
Several research firms have issued reports on CLRB. StockNews.com began coverage on shares of Cellectar Biosciences in a research report on Thursday, May 5th. They issued a “sell” rating on the stock. Zacks Investment Research cut shares of Cellectar Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, February 14th.
About Cellectar Biosciences (Get Rating)
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.
- Get a free copy of the StockNews.com research report on Cellectar Biosciences (CLRB)
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Inflation Hasn’t Peaked At Reynolds Consumer Products
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.